Liquid formulation of decitabine and use of the same
US6982253B2 · kind B2 · utility
12Cited by
10References
79Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 5, 2002 |
| Grant date | Jan 3, 2006 |
| Priority date | — |
| Expiry date | Oct 19, 2022 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Pharmaceutical formulations, kits and vessels are provided for delivering decitabine to a patient suffering from a disease in need of treatment with decitabine. The pharmaceutical formulation comprises decitabine solvated in a non-aqueous solvent that comprises glycerin, propylene glycol, polyethylene glycol, or combinations. Such formulations are more chemically stable than conventional liquid formulations of decitabine containing more than 40% water in volume. The pharmaceutical formulations can be used for any disease that is sensitive to the treatment with decitabine, such as hematological disorders and cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.